Analysis of gene expression profiling of amyloidogenic immunoglobulin light‑chains on cultured rat cardiomyocytes

Xu,Fei; Yu,Yue; Wang,Fang; Sun,Wei; Li,Peng; Wu,Heng‑Fang; Bian,Zhi‑Ping; Chen,Xiang‑Jian; Xu,Dong‑Jie

doi:10.3892/etm.2020.8610

Analysis of gene expression profiling of amyloidogenic immunoglobulin light‑chains on cultured rat cardiomyocytes

Authors:
- Fei Xu
- Yue Yu
- Fang Wang
- Wei Sun
- Peng Li
- Heng‑Fang Wu
- Zhi‑Ping Bian
- Xiang‑Jian Chen
- Dong‑Jie Xu
View Affiliations

Affiliations: Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: March 19, 2020 https://doi.org/10.3892/etm.2020.8610
Pages: 3767-3777
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the toxic effects of different amyloidogenic light‑chains (LCs) on cardiomyocytes, and demonstrate the differentially expressed genes (DEGs) and signaling pathways that participate in this process. Cultured cardiomyocytes were treated with recombinant κ LC peptide (AL‑09) or with serum from a patient diagnosed with multiple myeloma (λ LC) with cardiac involvement. The 6xHis peptide or serum from healthy patients was used as peptide control or serum control, respectively. Cell viability was determined using CCK‑8 assay and apoptosis was analyzed by flow cytometry. The DEGs were detected by RNA sequencing (RNA‑Seq), followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Changes in gene expression levels were confirmed by reverse transcription‑quantitative PCR. The cell viability in the AL‑09 peptide‑treated (0.2 mg/ml) and patient serum‑treated (1:10 dilution) cardiomyocytes decreased to 42 and ‑72% of the corresponding control groups. The extent of cell apoptosis increased in AL‑09‑treated cardiomyocytes compared with the control group. RNA‑Seq showed 256 DEGs co‑existed in the two paired groups, including 127 upregulated and 88 downregulated genes. The KEGG pathways for upregulated expressed genes included the ‘TGF‑β signaling pathway’, the ‘Hedgehog signaling pathway’, the ‘ErbB signaling pathway’ and ‘lysine degradation’. The higher mRNA expression of bone morphogenetic protein (Bmp) 4, Bmp6, prostaglandin G/H synthase (Ptgs)1, Ptgs2, epiregulin, Tgfa and procollagen‑lysine,2‑oxoglutarate 5‑dioxygenase 2 were confirmed. The KEGG pathways of downregulated expressed genes included genes involved with the ‘p53 signaling pathway’ and the ‘cell cycle’. The mRNA expression levels of E3 ubiquitin‑protein ligase CCNB1IP1 showed significant downregulation in the AL‑09 peptide group compared with those in the 6xHis peptide group. In conclusion, cardiomyocytes treated with amyloidogenic λ and κ LCs presented with decreased cell viability compared with controls. Cell apoptosis increased in κ LC‑treated cells compared with controls. The gene expression profiles associated with transforming growth factor‑β‑bone morphogenetic protein, the receptor tyrosine‑protein kinase erbB‑2 signaling pathways, prostaglandins, collagen production, the p53 signaling pathway and the cell cycle were altered in light‑chain‑treated cardiomyocytes.

View Figures

View References

1	Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, Falk RH and Apstein CS: Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 104:1594–1597. 2001.PubMed/NCBI
2	Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, Gianni D, Jiang B, Del Monte F, Connors LH, et al: Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol. 108(378)2013.PubMed/NCBI View Article : Google Scholar
3	Aimo A, Buda G, Fontana M, Barison A, Vergaro G, Emdin M and Merlini G: Therapies for cardiac light chain amyloidosis: An update. Int J Cardiol. 271:152–160. 2018.PubMed/NCBI View Article : Google Scholar
4	Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, et al: Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA. 107:4188–4193. 2010.PubMed/NCBI View Article : Google Scholar
5	Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D and Vorobiof G: Cardiac amyloidosis: Diagnosis and treatment strategies. Curr Oncol Rep. 19(46)2017.PubMed/NCBI View Article : Google Scholar
6	Tanaka K, Essick EE, Doros G, Tanriverdi K, Connors LH, Seldin DC and Sam F: Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J Am Heart Assoc. 2(e005868)2013.PubMed/NCBI View Article : Google Scholar
7	WRITING COMMITTEE MEMBERS. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, et al: 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 128:e240–e327. 2013.PubMed/NCBI View Article : Google Scholar
8	Lavatelli F, Imperlini E, Orru S, Rognoni P, Sarnataro D, Palladini G, Malpasso G, Soriano ME, Di Fonzo A, Valentini V, et al: Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB J. 29:4614–4628. 2015.PubMed/NCBI View Article : Google Scholar
9	Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS and Liao R: Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 94:1008–1010. 2004.PubMed/NCBI View Article : Google Scholar
10	Imperlini E, Gnecchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M, Malpasso G, et al: Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep. 7(15661)2017.PubMed/NCBI View Article : Google Scholar
11	Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, et al: Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med. 6:1493–1507. 2014.PubMed/NCBI View Article : Google Scholar
12	Pattison JS and Robbins J: Protein misfolding and cardiac disease: Establishing cause and effect. Autophagy. 4:821–823. 2008.PubMed/NCBI View Article : Google Scholar
13	Edwards HV, Cameron RT and Baillie GS: The emerging role of HSP20 as a multifunctional protective agent. Cell Signal. 23:1447–1454. 2011.PubMed/NCBI View Article : Google Scholar
14	Sikkink LA and Ramirez-Alvarado M: Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death Dis. 1(e98)2010.PubMed/NCBI View Article : Google Scholar
15	McLaughlin RW, De Stigter JK, Sikkink LA, Baden EM and Ramirez-Alvarado M: The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein. Protein Sci. 15:1710–1722. 2006.PubMed/NCBI View Article : Google Scholar
16	Baden EM, Owen BA, Peterson FC, Volkman BF, Ramirez-Alvarado M and Thompson JR: Altered dimer interface decreases stability in an amyloidogenic protein. J Biol Chem. 283:15853–15860. 2008.PubMed/NCBI View Article : Google Scholar
17	Louch WE, Sheehan KA and Wolska BM: Methods in cardiomyocyte isolation, culture, and gene transfer. J Mol Cell Cardiol. 51:288–298. 2011.PubMed/NCBI View Article : Google Scholar
18	Audic S and Claverie JM: The significance of digital gene expression profiles. Genome Res. 7:986–995. 1997.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Danilewicz M and Wagrowska-Danilewicz M: Immunohistochemical analysis of transforming growth factor beta-1 in AA and AL renal amyloidosis. Pol J Pathol. 57:193–198. 2006.PubMed/NCBI
21	Weiss R, Lifshitz V and Frenkel D: TGF-β1 affects endothelial cell interaction with macrophages and T cells leading to the development of cerebrovascular amyloidosis. Brain Behav Immun. 25:1017–1024. 2011.PubMed/NCBI View Article : Google Scholar
22	Lam HB, Yeh CH, Cheng KC, Hsu CT and Cheng JT: Effect of cholinergic denervation on hepatic fibrosis induced by carbon tetrachloride in rats. Neurosci Lett. 438:90–95. 2008.PubMed/NCBI View Article : Google Scholar
23	Adams SL, Benayoun L, Tilton K, Mellott TJ, Seshadri S, Blusztajn JK and Delalle I: Immunohistochemical analysis of activin receptor-like kinase 1 (ACVRL1/ALK1) expression in the rat and human hippocampus: Decline in CA3 during progression of Alzheimer’s disease. J Alzheimers Dis. 63:1433–1443. 2018.PubMed/NCBI View Article : Google Scholar
24	Papadopoulos P, Tong XK, Imboden H and Hamel E: Losartan improves cerebrovascular function in a mouse model of Alzheimer’s disease with combined overproduction of amyloid-beta and transforming growth factor-β1. J Cereb Blood Flow Metab. 37:1959–1970. 2017.PubMed/NCBI View Article : Google Scholar
25	Dobaczewski M, Chen W and Frangogiannis NG: Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 51:600–606. 2011.PubMed/NCBI View Article : Google Scholar
26	Villar AV, García R, Llano M, Cobo M, Merino D, Lantero A, Tramullas M, Hurlé JM, Hurlé MA and Nistal JF: BAMBI (BMP and activin membrane-bound inhibitor) protects the murine heart from pressure-overload biomechanical stress by restraining TGF-β signaling. Biochim Biophys Acta. 1832:323–335. 2013.PubMed/NCBI View Article : Google Scholar
27	Wu F, Yao H, Bader A, Dong F, Zhu F, Wu N, Wang B, Li H, Brockmeyer NH and Altmeyer P: Decorin gene transfer inhibited the expression of TGFbeta1 and ECM in rat mesangial cells. Eur J Med Res. 12:360–368. 2007.PubMed/NCBI
28	Lu J, Sun B, Huo R, Wang YC, Yang D, Xing Y, Xiao XL, Xie X and Dong DL: Bone morphogenetic protein-2 antagonizes bone morphogenetic protein-4 induced cardiomyocyte hypertrophy and apoptosis. J Cell Physiol. 229:1503–1510. 2014.PubMed/NCBI View Article : Google Scholar
29	Wu X, Sagave J, Rutkovskiy A, Haugen F, Baysa A, Nygård S, Czibik G, Dahl CP, Gullestad L, Vaage J and Valen G: Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart. Life Sci. 97:145–154. 2014.PubMed/NCBI View Article : Google Scholar
30	Banach J, Gilewski W, Slomka A, Buszko K, Błażejewski J, Karasek D, Rogowicz D, Żekanowska E and Sinkiewicz W: Bone morphogenetic protein 6-a possible new player in pathophysiology of heart failure. Clin Exp Pharmacol Physiol. 43:1247–1250. 2016.PubMed/NCBI View Article : Google Scholar
31	Knittel T, Fellmer P, Muller L and Ramadori G: Bone morphogenetic protein-6 is expressed in nonparenchymal liver cells and upregulated by transforming growth factor-beta 1. Exp Cell Res. 232:263–269. 1997.PubMed/NCBI View Article : Google Scholar
32	Yano R, Golbar HM, Izawa T, Sawamoto O, Kuwamura M and Yamate J: Participation of bone morphogenetic protein (BMP)-6 and osteopontin in cisplatin (CDDP)-induced rat renal fibrosis. Exp Toxicol Pathol. 67:99–107. 2015.PubMed/NCBI View Article : Google Scholar
33	Fattahi MJ and Mirshafiey A: Positive and negative effects of prostaglandins in Alzheimer’s disease. Psychiatry Clin Neurosci. 68:50–60. 2014.PubMed/NCBI View Article : Google Scholar
34	Bitto A, Giuliani D, Pallio G, Irrera N, Vandini E, Canalini F, Zaffe D, Ottani A, Minutoli L, Rinaldi M, et al: Effects of COX1-2/5-LOX blockade in Alzheimer transgenic 3xTg-AD mice. Inflamm Res. 66:389–398. 2017.PubMed/NCBI View Article : Google Scholar
35	Riese DJ II and Cullum RL: Epiregul in: Roles in normal physiology and cancer. Semin Cell Dev Biol. 28:49–56. 2014.PubMed/NCBI View Article : Google Scholar
36	Singh B, Carpenter G and Coffey RJ: EGF receptor ligands: Recent advances. F1000Res. 5(F1000)2016.PubMed/NCBI View Article : Google Scholar
37	Zhang H, Zhang L, Zhou D, He X, Wang D, Pan H, Zhang X, Mei Y, Qian Q, Zheng T, et al: Ablating ErbB4 in PV neurons attenuates synaptic and cognitive deficits in an animal model of Alzheimer’s disease. Neurobiol Dis. 106:171–180. 2017.PubMed/NCBI View Article : Google Scholar
38	White SK, Sado DM, Flett AS and Moon JC: Characterising the myocardial interstitial space: The clinical relevance of non-invasive imaging. Heart. 98:773–779. 2012.PubMed/NCBI View Article : Google Scholar
39	Du H, Pang M, Hou X, Yuan S and Sun L: PLOD2 in cancer research. Biomed Pharmacother. 90:670–676. 2017.PubMed/NCBI View Article : Google Scholar
40	Innocente SA, Abrahamson JL, Cogswell JP and Lee JM: p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA. 96:2147–2152. 1999.PubMed/NCBI View Article : Google Scholar
41	Milton NG: The amyloid-beta peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity. Neurosci Lett. 322:131–133. 2002.PubMed/NCBI View Article : Google Scholar
42	da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, et al: Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: Comparison with myeloma. Leukemia. 31:1735–1742. 2017.PubMed/NCBI View Article : Google Scholar